Nandrolone 17 Beta-Carbonates
AssigneeGovernment of the United States of America, Repre- Sented By the Secretary, Depa
InventorsRichard P. Blye, Hyun K. Kim
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds of the formula (I) wherein R is C1-C30 alkyl, which may be optionally further substituted with one or more C5-C8 cycloalkyl groups, or a C5-C12 cycloalkyl, which may be optionally substituted with one or more C1-C30 alkyl groups, R′ is hydrogen or lower alkyl, R″ is a C1-C30 alkyl or halo, and the bond between C14 and C15 can be a single bond or double bond. Also disclosed are pharmaceutical compositions comprising such compounds and methods of use thereof. These compounds can find use in treating a number of diseases or conditions such as hypogonadism, hypergonadism, osteoporosis, and anemia, in providing hormonal therapy and contraception, as an anabolic agent, and in suppressing the release of hormones such as the luteinizing hormone.
Claims53
A compound of formula (I):
- wherein R is a C1-C30 alkyl which may be optionally further substituted with one or more C5-C8 cycloalkyl groups or a C5-C12 cycloallyl which may be optionally substituted with one or more C1-C30 alkyl groups;
- R′ is hydrogen or lower allyl;
- R″ is a C1-C30 alkyl or halo;
- and the bond between C14 and C15 can be a single bond or double bond.
A method of suppressing the release of luteinizing hormone in a mammal comprising administering to the mammal an effective amount of 7α,11β-dimethyl-19-nortestosterone-17-decylcarbonate.
Dependencies are inferred from the claim text.